bioAffinity Granted Hong Kong Patent for CyPath Lung Diagnostics
The Hong Kong Intellectual Property Department granted a patent for CyPath Lung, reinforcing the company's intellectual property portfolio in Asia, a region accounting for nearly two-thirds of global lung cancer cases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed